Previous 10 | Next 10 |
2023-11-29 08:23:49 ET Losers: Seelos Therapeutics ( SEEL ) -43% on pricing of $5.55 million stock offering . Leslies ( LESL ) -20% after Q4 earnings release . Farfetch Ltd ( FTCH ) -16% . ESGL Holdings Ltd ( ESGL ) -15% . Petco ...
2023-11-07 14:56:04 ET Summit Therapeutics Inc. (SMMT) Q3 2023 Results Conference Call November 07, 2023 09:00 AM ET Company Participants Dave Gancarz - Chief Business and Strategy Officer Bob Duggan - Chairman of the Board and Chief Executive Officer Dr. Maky Za...
2023-11-07 07:14:34 ET More on Summit Therapeutics Summit Therapeutics: Not For Retail Investors Navigating Summit Therapeutics' Bispecific Bet Amid Cash Constraints Summit Therapeutics, Inc. (SMMT) Q2 2023 Earnings Call Transcript Financial information for S...
Enrollment Initiated in Second Phase III Clinical Study for Ivonescimab, HARMONi-3 Continuing Enrollment of HARMONi Phase III Study, with Enrollment Completion Expected in Second Half of 2024 Manmeet S. Soni Joined Summit as COO, Invested $5 Million in the Company Dave Gan...
Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...
Summit Therapeutics Inc. (SMMT) is expected to report for Q1 2024
2023-11-06 09:00:00 ET Summary Acurx is a promising antibiotic company with perfect Phase 2a data in treating C. difficile infection. The company is developing a novel antibiotic, ibezapolstat, which could be the first new class of antibiotics in decades. Ibezapolstat has show...
Dr. Chow Brings Two Decades of Immunotherapy & Anti-Angiogenic Cancer Treatment Experience to Team Summit Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Laura Chow, MD, has joined Summit Thera...
Potential First-in-Class Tetravalent Bispecific Antibody Demonstrates Enhanced Binding in the Simultaneous Presence of PD-1 & VEGF Cooperative Binding of SMT112 Enables Higher Avidity in the Tumor Microenvironment with Over 18 Fold Increased Binding Affinity to PD-1 in the Presence of...
Conference Call to Be Held at 9:00am ET Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its third quarter 2023 financial results and provide an operational update for the Company ...
News, Short Squeeze, Breakout and More Instantly...
Summit Therapeutics Inc. Company Name:
SMMT Stock Symbol:
NASDAQ Market:
U.S. stocks were higher, with the Dow Jones gaining over 80 points on Tuesday. Shares of Tempur Sealy International, Inc. (NYSE:TPX) rose sharply d...
2024-05-07 07:15:07 ET Citigroup analyst issues BUY recommendation for SMMT on May 7, 2024 05:12AM ET. SMMT was trading at $4.47 at issue of the analyst recommendation. Historical Analyst Recommendations Latest 10 recommendations
HARMONi and HARMONi-3 Enrollment Continues Promising Intracranial Anti-Tumor Activity and Safety Data Featured at the 2024 European Lung Cancer Congress with Ivonescimab Alone or Combined with Chemotherapy Achieving 34% Intracranial Responses; Median Intracranial PFS of 19.3 months in NSC...